GlassScriptPhysician profile
Dawn J Caster
NPI 1659402287
$192,809.71
in general payments reported to CMS, 2019-2025
15 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,943 · 2020: $7,032 · 2021: $18K · 2022: $35K · 2023: $42K · 2024: $60K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $46K · Consulting Fee: $45K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,565 · Food and Beverage: $3,663 · Grant: $1,039 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $45,675.00 |
| Consulting Fee | $45,055.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,300.00 |
| Travel and Lodging | $13,231.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,565.00 |
| Food and Beverage | $3,663.42 |
| Grant | $1,038.78 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $66,058.52 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $45,752.44 | 2020-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $32,860.46 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $21,347.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $14,706.44 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $8,863.77 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $2,680.00 | 2024 | |
| Amgen INC. | $215.44 | 2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $138.08 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2022 | |
| Genentech, INC. | $53.45 | 2025 | |
| Vifor Pharma, INC. | $22.09 | 2019 | |
| Baxter Healthcare | $11.49 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Caster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.